Neoadjuvant/Adjuvant Pembrolizumab Regimens Lower RCB in ER+ Breast Cancer
Neoadjuvant pembrolizumab (Keytruda) plus chemotherapy, followed by adjuvant pembrolizumab combined with endocrine therapy, lowered residual cancer burden (RCB) and did not have an impact on adverse effects (AEs) compared with neoadjuvant placebo/ …